Biblio
Export 751 results:
Author [ Title] Type Year Filters: First Letter Of Keyword is P [Clear All Filters]
“Chronic Sleep Deprivation Exacerbates Learning-Memory Disability and Alzheimer's Disease-Like Pathologies in AβPP(swe)/PS1(ΔE9) Mice.”, J Alzheimers Dis, vol. 50, no. 3, pp. 669-85, 2016.
, “Chronic Sleep Deprivation Exacerbates Learning-Memory Disability and Alzheimer's Disease-Like Pathologies in AβPP(swe)/PS1(ΔE9) Mice.”, J Alzheimers Dis, vol. 50, no. 3, pp. 669-85, 2016.
, “Chronic Sleep Deprivation Exacerbates Learning-Memory Disability and Alzheimer's Disease-Like Pathologies in AβPP(swe)/PS1(ΔE9) Mice.”, J Alzheimers Dis, vol. 50, no. 3, pp. 669-85, 2016.
, “Cigarette Smoke-Induced Alterations in Frontal White Matter Lipid Profiles Demonstrated by MALDI-Imaging Mass Spectrometry: Relevance to Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 151-63, 2016.
, “Cigarette Smoke-Induced Alterations in Frontal White Matter Lipid Profiles Demonstrated by MALDI-Imaging Mass Spectrometry: Relevance to Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 151-63, 2016.
, “Cigarette Smoke-Induced Alterations in Frontal White Matter Lipid Profiles Demonstrated by MALDI-Imaging Mass Spectrometry: Relevance to Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 151-63, 2016.
, “Circulating Progenitor Cells Correlate with Memory, Posterior Cortical Thickness, and Hippocampal Perfusion.”, J Alzheimers Dis, vol. 61, no. 1, pp. 91-101, 2018.
, “Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 839-45, 2016.
, “Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 839-45, 2016.
, “Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 839-45, 2016.
, “Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 701-11, 2016.
, “Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 701-11, 2016.
, “Cleveland Clinic Cognitive Battery (C3B): Normative, Reliability, and Validation Studies of a Self-Administered Computerized Tool for Screening Cognitive Dysfunction in Primary Care.”, J Alzheimers Dis, vol. 92, no. 3, pp. 1051-1066, 2023.
, “Clinical and Demographic Factors Associated with the Cognitive and Emotional Efficacy of Regular Musical Activities in Dementia.”, J Alzheimers Dis, vol. 49, no. 3, pp. 767-81, 2016.
, “Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes.”, J Alzheimers Dis, vol. 49, no. 3, pp. 695-705, 2016.
, “Clinical utility of the informant AD8 as a dementia case finding instrument in primary healthcare.”, J Alzheimers Dis, vol. 49, no. 1, pp. 121-7, 2016.
, “A Clinically-Translatable Machine Learning Algorithm for the Prediction of Alzheimer's Disease Conversion in Individuals with Mild and Premild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1555-1573, 2018.
, “A Clinically-Translatable Machine Learning Algorithm for the Prediction of Alzheimer's Disease Conversion in Individuals with Mild and Premild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1555-1573, 2018.
, “Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.”, J Alzheimers Dis, vol. 61, no. 1, pp. 135-143, 2018.
, “Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.”, J Alzheimers Dis, vol. 61, no. 1, pp. 135-143, 2018.
, “Co-Expression of Glia Maturation Factor and Apolipoprotein E4 in Alzheimer's Disease Brain.”, J Alzheimers Dis, vol. 61, no. 2, pp. 553-560, 2018.
, “The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1145-55, 2016.
, “Cognitive Decline Risk Stratification in People with Late-Onset Epilepsy of Unknown Etiology: An Electroencephalographic Connectivity and Graph Theory Pilot Study.”, J Alzheimers Dis, vol. 88, no. 3, pp. 893-901, 2022.
, “Cognitive, Functional, and Emotional Changes During the COVID-19 Pandemic in Greek Patients with Neurocognitive Disorders.”, J Alzheimers Dis, vol. 88, no. 2, pp. 537-547, 2022.
, “Cognitive Impairment after Mild Stroke: Development and Validation of the SIGNAL2 Risk Score.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1169-77, 2016.
,